CTI Partners with Humanigen for Planned Phase II Study for Lenzilumab for Coronavirus Treatment

“The COVID-19 pandemic demands an unprecedented response from the pharmaceutical and biotechnology communities, requiring innovation, collaboration, and prioritization of speed without the cost of safety,” remarked Tim Schroeder, founder and CEO of CTI. "We are proud to have the opportunity to collaborate on such a response with the Humanigen team and to work together to develop an effective treatment solution for those hardest hit by COVID-19.”

CTI Announces US Expansion on East and West Coasts

"We're excited to continue growing across the United States outside of our headquarters in Covington," remarks Timothy J. Schroeder, Founder and CEO. "The expanded office in Raleigh and the new office in San Francisco will allow us to continue to accommodate our ever expanding workforce and to tap into the rich populations in both cities for new talent."

CTI Honored at 2019 Innovation & Technology Awards

"We're honored to be chosen by the Cincinnati Business Courier as a finalist for this award recognizing our team's innovative work," remarks Timothy J. Schroeder, Founder and CEO. "It is an exciting time in the drug development industry in which we are able to work on programs that don't just treat diseases, but may ultimately cure them. Our success is a testament to the dedication of our employees, and we look forward to seeing what further medical advances come from their hard work."

Bexion and CTI Announce Completion of First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

“CTI is extremely happy to partner with Bexion on the development of this novel therapy in patients who desperately need alternative treatments,” stated William Aronstein, PhD, MD, FACP, Vice President, Medical Affairs at CTI. “They are an innovative organization with very strong regional ties – the drug was initially developed and licensed at a local hospital, early funding has predominantly come from the region, and the management and board have strong local connections.”


Regenerative Medicine / Gene Therapy

With more the 50% of CTI's active prospective studies involving regenerative medicine, including contributing to the development program of several of the world's first approved gene therapy products, the company is a leader in the field.

Learn More

eCTD Publishing

CTI has the expertise needed to help our sponsors understand and comply with document submission requirements.

Learn More

Why We Work at CTI

There's a reason we have one of the highest retention rates in the industry. We value our people, and we work hard to make sure our team members know it.

Learn More

Participate in a trial

Icon Careers Small Retina

CTI CRC is looking for volunteers to participate in our current trials. 

Learn More

Join our team

Icon Careers Small Retina

CTI is always looking for talented individuals to work on life-changing therapies around the world

Learn More